In Patients With Diabetes, Metformin is Linked to Improved Outcomes in Patients With HER2-Positive, Hormone-Receptor-Positive Breast Cancer

An analysis of data from the ALTTO study suggests that women with diabetes treated with metformin who have been diagnosed with HER2-positive, hormone-receptor-positive breast cancer have better outcomes, including overall survival, than similar women who were not treated with metformin.